The Latest Cardiac and Vascular News
MOUNTAIN VIEW, Calif., Oct. 8, 2024 /PRNewswire/ — The radiology department of Louis Stokes Cleveland VA Medical Center (LSCVAMC) has chosen HealthLevel’s radiology business operations platform, Foundations™, to enhance patient care and boost the operational efficiency of its clinical…
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension (BOLD-HTN) supported by a recent round of financing.
Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity TAMPA, Fla., Oct. 8, 2024 /PRNewswire/ — EMBLOK™ (emblok.com), a privately held medical device company developing the most…
HENRICO, Va. and RALEIGH, N.C., Oct. 8, 2024 /PRNewswire/ — Compass Surgical Partners, Bon Secours Mercy Health and AlignedCardio today announced their plans to open Short Pump Cardiovascular Ambulatory Surgery Center in the Short Pump area of Henrico, Virginia. Scheduled to open in late…
Partnership to Deliver Next-Generation AI Solutions for Radiologists KNOXVILLE, Tenn. and MOUNTAIN VIEW, Calif., Oct. 8, 2024 /PRNewswire/ — RADPAIR, a leader in generative AI-driven radiology reporting solutions, is excited to announce the launch of RADPAIR 2.0, the next iteration of…
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology’s (ASN) Kidney Week 2024. The late-breaking abstract titled “Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access” will be presented at the ASN meeting in San Diego on October 26, 2024.
BERKELEY HEIGHTS, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 200 outpatient dialysis clinics located across the United States.
Program reduced all-cause 30-day readmissions for CHF patients by 50 percent using a combination of AI-powered technology and remote human care teams. SOUTHBRIDGE, Mass., Oct. 8, 2024 /PRNewswire/ — UMass Memorial Health – Harrington (“Harrington”), the health and wellness provider for…
HOUSTON, Oct. 8, 2024 /PRNewswire/ — Octagos Health, the leader in AI-powered remote cardiac monitoring, today announced significant advancements in product integration, enhanced AI functionality, and strategic talent investments. Following its recent $43 million Series B funding, the…
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
